<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01284322</url>
  </required_header>
  <id_info>
    <org_study_id>H30142</org_study_id>
    <nct_id>NCT01284322</nct_id>
  </id_info>
  <brief_title>Fresolimumab In Systemic Sclerosis</brief_title>
  <official_title>OPEN LABEL TRIAL OF ANTI-TGF-BETA MAB, FRESOLIMUMAB, IN SYSTEMIC SCLEROSIS - A PHASE ONE BIOMARKER TRIAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if fresolimumab is safe in treating people with&#xD;
      systemic sclerosis (scleroderma) and to investigate the effect of fresolimumab in the skin of&#xD;
      these individuals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate safety of fresolimumab in patients with scleroderma</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the effect of fresolimumab on TGF-beta responsive gene expression in skin after treatment with fresolimumab compared to pre-treatment TGF-beta responsive gene expression.</measure>
    <time_frame>7 weeks</time_frame>
    <description>TGF-beta regulated skin gene expression</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Diffuse Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Fresolimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fresolimumab</intervention_name>
    <description>intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients</description>
    <arm_group_label>Fresolimumab</arm_group_label>
    <other_name>GC1008</other_name>
    <other_name>anti-TGF-beta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet ACR criteria for diffuse systemic sclerosis&#xD;
&#xD;
          -  &lt; 24 months since onset of first SSc manifestation other than Raynaud's phenomenon&#xD;
&#xD;
          -  Modified Rodnan Skin Score ≥ 15&#xD;
&#xD;
          -  Male or female adult ( ≥ 18 years of age)&#xD;
&#xD;
          -  Able and willing to give written informed consent and comply with study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Moderate or severe pulmonary disease w/ FVC &lt; 80% or DLCO &lt; 70% or ground glass and&#xD;
             fibrosis &gt; 20% of lung fields by HRCT&#xD;
&#xD;
          -  Treatment with investigational drug within 4 weeks of screening&#xD;
&#xD;
          -  Ongoing use of high dose steroids (&gt; 10mg/day) or unstable steroid dose in past 4&#xD;
             weeks&#xD;
&#xD;
          -  Treatment with immunosuppressive, cytotoxic, or antifibrotic drug within 4 weeks of&#xD;
             screening&#xD;
&#xD;
          -  Positive for HIV, HBV, and/or HCV&#xD;
&#xD;
          -  Known active infection (bacterial, viral, fungal, mycobacterial, or other); not&#xD;
             including fungal infection of nail beds or any major infection requiring&#xD;
             hospitalization or treatment with IV antibiotics within 4 weeks of screening&#xD;
&#xD;
          -  Patients w/ history of malignancy or premalignant lesion&#xD;
&#xD;
          -  History of keratoacanthoma or squamous cell carcinoma&#xD;
&#xD;
          -  Moderate to severe hepatic impairment&#xD;
&#xD;
          -  SSc renal crisis within 6 months or creatinine &gt; 2.0&#xD;
&#xD;
          -  Lack of IV access for medication administration&#xD;
&#xD;
          -  Moderate or severe cardiac disease with significant arrhythmia, heart failure, or&#xD;
             unstable angina&#xD;
&#xD;
          -  Anemia (Hb &lt; 8.5 gm/dL)&#xD;
&#xD;
          -  Thrombocytopenia or blood clotting disorder&#xD;
&#xD;
          -  Patients with organ transplant (including allogeneic bone marrow transplant)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Lafyatis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University School of Medicine; Rheumatology/Arthritis Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>January 25, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2011</study_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston University</investigator_affiliation>
    <investigator_full_name>Robert Lafyatis</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

